Tools
Back to Results

Assessing Treatments for Patients with Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer


Title Lung Cancer - Assessing Treatments for Patients with Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer
Therapeutic Area Lung Cancer
Principal Investigator Krishna Gunturu, MD
Min Age 18 Years
Gender Both
Contact Jennifer Caplain, RN
617-636-9161

Overview

The primary purpose of the trial is to study the safety of combination therapy with chemoradiation, followed by consolidation, finally followed by the investigational drugs L-BLP25 and bevacizumab for patients with non-squamous, locally advanced Non Small Cell Lung Cancer (NSCLC).The other reasons for this study are to: study overall survival, toxicity, and progression-free survival for patients treated with L-BLP25 plus bevacizumab in addition to chemoradiation and consolidation therapy.

Study Details

Inclusion Criteria

  • Potential subjects must have newly diagnosed histologically confirmed non-squamous non small cell lung cancer
  • Surgery to remove the cancer is not an option
  • Potential subjects must have adequate liver, kidney, and heart function

Exclusion Criteria

  • The potential subject cannot have brain/ spinal fluid metastases, or any other active cancers
  • Potential subjects cannot have had previous chemotherapy or radiation therapy for lung cancer
  • Potential subjects cannot have an active infection, have any autoimmune disease or have an immunodeficiency disease

Study Requirements

Standard Chemoradiotherapy (radiation+chemotherapy drugs) during the week for 6.5 weeks, then 6 weeks of Standard Chemotherapy, then 24 months of study drugs L-BLP25 plus bevacizumab.  During this time, there will be standard urine tests, blood tests, physical exams, and CT scans (3, then 1 every 9 weeks during study drug period). 
Nurse navigators for cancer patients at Tufts Medical Center.

Are you interested in learning more about this clinical trial?

Send us a message and we'll get back to you with more information.

Request information